cony16

CONy16: Should RRMS Disease-Modifying Drugs Be Used to Treat Secondary Progressive MS?

A majorĀ dilemma facing clinicians is whether to continue treatment withĀ disease-modifying drugs, effective in relapsing-remitting multiple sclerosis (RRMS), as the disease progresses to secondary progressive MS (SPMS). In SPMS, Ā these treatments seem to lose their benefits and ā€” as they areĀ often associated with severe side effects and high costs ā€” clinicians…

CONy16: Sanofi Genzyme Symposium on MS Therapies Targeting T and B Cells; Exclusive Interview with Lead Researcher

Sanofi Genzyme,Ā one of the companies participatingĀ in the four-dayĀ 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concludedĀ on March 20, 2016, supported several symposiums focused on multiple sclerosis (MS) ā€” including one on B-cell and T-cell therapies. For over a decade, Sanofi Genzyme has workedĀ to developĀ effective therapies…

CONy16: Debate Weighs MS Therapy Risks of Infections Like PML in Terms of Benefits Offered

Certain therapies used toĀ treat multiple sclerosis (MS) have been associated with opportunistic infections of the central nervous system, including progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain disorder caused by the John Cunningham (JC) virus. The question of whether the risk for opportunistic infections to MS patients outweighs…

#CONy16: Scientists Debate MRI’s Role in MS Treatment Changes; Exclusive Interview with Prof. Xavier Montalban

The precision of magnetic resonance imaging (MRI) measurement has improved over the years, and now scans can identify brain damage before symptoms begin showing. Whether the presence of new or expanding lesions predict disease progression is, however, still controversial, and clinicians have no guidance when making treatment decisions about the…